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Available online 26 July 2016The current ﬁrst-line therapy for drug-susceptible tuberculosis consists of rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA) and ethambutol (EMB). In this study, we determined the population pharmacokinetics
(PopPK) of RIF, INH, EMB and PZA using original experimental sampling designs for single-dose intravenous
(IV) and single- andmultiple-dose oral administration studies in themousemodel, and used these PopPKmodels
to develop and evaluate new,more informative sampling designswith the aimof reducing the number of animals
required for each drug.
The RIF, INH, EMB and PZA blood concentrations after single oral and IV doses andmultiple-dose oral administra-
tions based on the original designs were used in the PopPK analysis using NONMEM software. The ﬁnal PopPK
models described the data well. Stochastic simulation and estimation were used to optimise the designs. The rel-
ative bias and relative imprecision of each pharmacokinetic parameter for each drug were derived and assessed
to choose the ﬁnal designs. The ﬁnal single-dose IV and oral designs included up to eight samples permousewith
a total of 24mice required for RIF and EMB and 33 mice for INH and PZA. In the newmultiple-dose (zipper) oral
designs, themice were divided into two groups of three per dose, and four samples were taken from eachmouse
to cover all seven or eight sampling time points. The ﬁnal number ofmice required for themultiple-dose oral de-
signs was 30 for RIF, INH and EMB, 36 for PZA. The number of mice required in the new designs for RIF, INH and
EMBwas decreased byup to 7-fold and the relative bias and relative imprecision in the parameter estimateswere
at least similar to those in the original designs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pyrazinamide1. Introduction
Tuberculosis (TB), an infectious disease caused byMycobacterium tu-
berculosis (M. tuberculosis) which most commonly affects the lungs
(pulmonary TB) but can also affect other organs (extra-pulmonary
TB), is a major global health problem. The current ﬁrst-line therapy for
drug-susceptible TB consists of rifampicin (RIF), isoniazid (INH), etham-
butol (EMB) andpyrazinamide (PZA). The treatment period of 6months
for drug-susceptible TB is associated with a risk of poor compliance, the
occurrence of drug resistance, a high risk of relapse and treatment fail-
ure. It would therefore be preferable if the treatment duration for new
therapies was reduced. Identiﬁcation of new therapies is dependent
on various animal models such as mouse, rabbit and guinea pig. Of
these species, the mouse is the primary animal species used for pre-. This is an open access article underclinical anti-TB drug development because of ease of handling, low
costs and susceptibility toM. tuberculosis.
Pharmacometrics is an emerging science that quantitatively anal-
yses the pharmacokinetics (PK) and pharmacodynamics (PD) of
drugs, i.e. their efﬁcacy and safety. In drug development, it is impor-
tant to establish exposure-response relationships, preferably for
both efﬁcacy and safety, at an early stage. If these relationships are
deﬁned early in the process, during pre-clinical animal studies or in
vitro studies using biomarkers, the information can be used to deﬁne
the likely dose range for use in Phase II studies in humans. Pharma-
cokinetic data are essential for deﬁning these relationships, regard-
less of the stage of the drug in development. Nonlinear mixed
effects modelling is employed in the so-called population approach
in pharmacometric analysis. It also reliably estimates inter-individu-
al variability (IIV) and inter-occasion variability (IOV), and separates
these from residual variability. Pharmacokinetic and pharmacody-
namic experimental designs need to be optimised in order to reducethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of original and new study designs for pharmacokinetic characterisation of rifampicin (RIF) in themouse model. The number of doses and animals, blood-sampling time points,
number of samples/animal and number of observations (animals used)/time point for the original designs, the new single-dose intravenous (IV) and oral (PO) designs and the new zipper
design for multiple-dose PO administrations are given. The light grey numbers show the identifying number for each animal used in the design to illustrate the time point at which the
sample was taken from that animal.
a Data from the new single-dose IV design were analysed simultaneously with the new multiple-dose PO data to obtain steady-state PK results.
b Samples were taken at these times each day for three days.
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collected. This is preferably done using pharmacometric models
and techniques, as shown in this work.
The objectives of this workwere to describe the population pharma-
cokinetics (PopPK) of RIF, INH, EMB and PZA in the mouse using blood
concentrations, and to optimise the PK sampling designs for these
anti-TB drugs using a PopPK model for each drug, while aiming to re-
duce the number of animals required in PopPK studies.2. Material and methods
2.1. Chemicals
All chemicals and reagents were obtained from Sigma-Aldrich
(Spain). Water was puriﬁed and de-ionised using a Water PuriﬁedTable 2
Summary of original and new study designs for pharmacokinetic characterisation of isoniazid (
number of samples/animal and number of observations (animals used)/time point for the origin
design for multiple-dose PO administrations are given. The light grey numbers show the ident
sample was taken from that animal.
a Data from the new single-dose IV design were analysed simultaneously with the new mult
b Samples were taken at these times each day for three days.
c Samples were taken at 8 h post-dose only for the 5 mg/kg and 25 mg/kg doses.System (Milli-Q water). The drugs were administered in the following
vehicles: RIF in 20% encapsin/80% saline for both the IV and oral routes;
INH inMilli-Q water for both the IV and oral routes; EMB and PZA in sa-
line for the IV route and 1% methyl cellulose for the oral route.2.2. Pharmacokinetic study in mice
Healthy C57BL/6 mice (8–10 weeks old, Harlan Laboratories) were di-
vided into four groups with similar average weights (18.8 g) and each
group was administered RIF, INH, EMB or PZA in solution via oral gavage
(20 mL/kg) or IV bolus injection (10 mL/kg). Rifampicin was given as a
single IV dose (12 mg/kg), a single oral dose (1, 3, 10, 30 or 100 mg/kg)
or multiple oral doses (10 mg/kg/day) for three days. Isoniazid was
given as a single IV dose (10 mg/kg), a single oral dose (0.2, 0.5, 1, 5 or
25 mg/kg) or multiple oral doses (25 mg/kg/day) for three days.INH) in the mouse model. The number of doses and animals, blood-sampling time points,
al designs, the new single-dose intravenous (IV) and oral (PO) designs and the new zipper
ifying number for each animal used in the design to illustrate the time point at which the
iple-dose PO data to obtain steady-state PK results.
Table 3
Summaryof original andnew studydesigns for pharmacokinetic characterisation of ethambutol (EMB) in themousemodel. The number of doses and animals, blood-sampling timepoints,
number of samples/animal and number of observations (animals used)/time point for the original single-dose designs (a multiple-dose study was not performed), the new single-dose
intravenous (IV) and oral (PO) designs and the new zipper design for multiple-dose PO administrations are given. The light grey numbers show the identifying number for each animal
used in the design to illustrate the time point at which the sample was taken from that animal.
a Data from the new single-dose IV design were analysed simultaneously with the new multiple-dose PO data to obtain steady-state PK results.
b Samples were taken at 24 h post-dose only for the 300 mg/kg and 1000 mg/kg doses.
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(10, 30, 100, 300 or 1000mg/kg). Therewas nomultiple-dose regimen for
EMB. Pyrazinamide was given as a single IV dose (25mg/kg), a single oral
dose (15, 25, 50, 150, 400 or 1000mg/kg) ormultiple oral doses (150mg/
kg/day) for four days. All mice received treatment in the fed state.
In the experiments using the original sampling design for single oral
and IV administrations of RIF, INH and EMB, only one blood sample was
taken from each mouse, at each of nine to ten time points per dose, and
three mice were used for each time point. The blood samples were
taken by cardiac puncture after the animal had been euthanised by
CO2. For PZA, one sample was taken from each euthanised mouse forTable 4
Summary of original and new study designs for pharmacokinetic characterisation of pyrazina
points, number of samples/animal and number of observations (animals used)/time point for
new zipper design for multiple-dose PO administrations are given. The light grey numbers sh
at which the sample was taken from that animal.
a Data from the new single-dose IV design were analysed simultaneously with the new mult
b Samples were taken at these times each day for four days.
c Samples were taken at 0.75 h instead of at 24 h post dose for the 400 mg/kg and 1000 mg/the single IV dose, but repeated samples were taken from the lateral
tail vein of each mouse at seven or eight time points after each single-
dose oral administration. In the original designs for multiple-dose oral
administrations, four samples were taken from the tail veins of each
mouse each day for three days for RIF and INH and for four days for
PZA. All the blood samples were frozen at−70 °C till analysis by ultra-
performance liquid chromatography-tandemmass spectrometry (UPLC-
MS/MS). The number of doses, sampling time points, number of animals
used per dose, total number of animals used, number of samples taken
per animal and number of animals used for sampling at each time point
are given under the heading ‘Original designs’ in Tables 1 to 4.mide (PZA) in the mouse model. The number of doses and animals, blood-sampling time
the original designs, the new single-dose intravenous (IV) and oral (PO) designs and the
ow the identifying number for each animal used in the design to illustrate the time point
iple-dose PO data to obtain steady-state PK results.
kg doses.
Fig. 1. Observed blood concentrations versus time for the original sampling designs after A) rifampicin (RIF) single-dose intravenous (IV) or single-dose oral (PO), B) isoniazid (INH)
single-dose IV or single-dose PO, C) ethambutol (EMB) single-dose IV or single-dose PO, D) pyrazinamide (PZA) single-dose IV or single-dose PO and E) multiple-dose PO of RIF, INH
and PZA.
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acetonitrile/methanol (80:20), containing an internal standard, and
were analysed by UPLC-MS/MS in positive ion mode with
electrospray, using multiple reaction monitoring at the speciﬁc
mass transitions for RIF, INH, EMB and PZA. The limit of quantiﬁca-
tion (LOQ) was 10 ng/mL for RIF, 5 ng/mL for INH and EMB, and
100 ng/mL (after IV administration) and 500 ng/mL (after oral ad-
ministration) for PZA.
The studies were ethically reviewed and carried out in accordance
with European Directive 86/609/EEC and the GSK Policy on the Care,
Welfare and Treatment of Animals.
2.3. Population pharmacokinetic modelling and evaluation
All modellingwas conducted usingNONMEM7.2 software (Icon De-
velopment Solutions, Ellicott City, MD) and the ﬁrst-order conditional
estimation method. Perl-speaks-NONMEM (PsN) (version 4.2.0)
(http://psn.sourceforge.net/; Keizer et al., 2013) was used to create a
prediction-corrected visual predictive check (pcVPC) (Bergstrand et
al., 2011). Rstudio (version 2.14.2) was used for graphical analysis anddata management. Xpose (version 4.4.1) (http://xpose.sourceforge.
net/; Keizer et al., 2013) was used for visualisation of data and results.
Run record was produced with Pirana software (version 2.8.0) (http://
www.pirana-software.com/; Keizer et al., 2011). Proportional, additive
and combined errormodelswere evaluated in order to describe residual
variability.
Model selection was based on the change in the objective function
value (OFV). A decrease of 3.84 after addition of a single parameter for
nested models was considered signiﬁcant, corresponding to a 5% signif-
icance level with one degree of freedom. Scientiﬁc plausibility, parame-
ter precision, goodness-of-ﬁt plots and pcVPC were also considered in
the process of model selection.
All the blood concentrations of each drug (obtained using the origi-
nal sampling designs) were modelled simultaneously using a nonlinear
mixed effects approach. Initially, one- and two-compartmental struc-
tural PKmodels, with ﬁrst-order absorption and elimination,were eval-
uated. For PZA, a three-compartmentalmodelwas also evaluated due to
data-driven observations. Dose dependence and time dependencewere
also tested for RIF, INH and PZA. Only dose dependence was evaluated
for EMB since there was no PK information available from multiple-
Table 5
Final pharmacokinetic parameter estimates for rifampicin (RIF), isoniazid (INH), etham-
butol (EMB) and pyrazinamide (PZA) in the mouse, based on blood concentrations and
the original sampling designs.
Parameters RIF INH EMB PZA
Typical
value
RSE
(%)
Typical
value
RSE
(%)
Typical
value
RSE
(%)
Typical
value
RSE
(%)
ka (h−1) 1.02 15.2 12.6 12.1 0.869 9.9 2.84 11.2
CL (mL/h/kg)a 79.3 11.4 855 8.2 2560 5.9 515 5.3
V (mL/kg) 1250 4.3 989 4.2 2180 12.8 532 5.8
Q (mL/h/kg) – – – – 1760 13.5 43.8 23.5
V2 (mL/kg) – – – – 4910 7.6 709 18.9
F (%) 65.6 6.4 84.3 4.8 64.0 6.7 55.9 8
Tlag (h−1) – – – – 0.0577 11.1 – –
Vlowest dose
(mL/kg)
2280 8.4 437 13 – – – –
CLhighest dose
(mL/h/kg)
– – – – – – 95 17.1
CLMAX (%) – – 75.2 25.9 – – – –
CL50 (μg/kg) – – 17,500 67.4 – – – –
CL at Day 3
(mL/h/kg)
132 9.5 – – – – – –
IIV in CL (%) 15.9 23.3 14.6 16.5 – – 27.8 14.7
IIV in ka (%) 55.6 22 – – – – – –
IIV in V (%) 21.8 23.6 – – – – – –
IIV in Q (%) – – – – – – 118.7 19.5
IOV in F (%) 15.6 20.8
CL= clearance; CLhighest dose = CL at the highest dose level; CLMAX = the maximum per-
centage decrease in CL of isoniazid; CL50 = the dose level at which CL reached 50% of
CLMAX for isoniazid; F = bioavailability; IIV = inter-individual variability expressed as
the coefﬁcient of variation and as a percentage of the parameter estimate; IOV= inter-oc-
casional variability expressed as the coefﬁcient of variation and as a percentage of the pa-
rameter estimate; ka = absorption rate constant; Q = intercompartmental rate; RSE =
relative standard error reported on the approximate standard deviation scale; Tlag =
absorption lag time; V= volume of distribution; Vlowest dose = V at lowest oral dose.
a Rifampicin clearance during Days 1 and 2.
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were evaluated on all ﬁxed effects using log-normal distribution:
Pi ¼ P  exp ηi
 
where Pi is the value of the parameter in individual i, P is the typical
value of the parameter in a population and ŋi is the normally distributed
IIV with a mean 0 and variance ω2.
The percentage of data below the LOQ for PZAwas 18.8%. Therewere
no RIF, INH and EMB blood concentration observations below the LOQ.
Attempts were made to use the M3 method in NONMEM for modelling
PZA PK but this was not successful, because there was no improvement
in OFV. Therefore, data below the LOQ was handled by setting the ﬁrst
LOQ observation to half of the LOQ value.
2.4. Design optimisation and sample size determination
A stochastic simulation and estimation (SSE) approach was uti-
lized for the developed PopPK models for each of the four drugs in
order to optimise the sampling designs and decrease the number of
animals required. Different sampling schemes and numbers of mice
were evaluated for each drugwith the aim of reducing the total num-
ber of animals required while retaining at least the same relative im-
precision and relative bias (rBias) in the ﬁxed and random effects
parameters. The new designs for each drug were optimised for
both single-dose and multiple-dose experiments with the PK data
obtained on one occasion (the multiple-dose designs used single-
dose IV design plus single-dose oral design at steady-state). For the
single-dose designs, the number of samples per animal was in-
creased to eight, which was judged to be practical and ethically jus-
tiﬁed. This allowed the capture of more PK information from eachanimal while reducing the total number of animals in comparison
with the original design from which the PK data were obtained to
build the PopPK models. For the single-dose design, other scenarios
explored included extending the sampling period to 24 h post-
dose, varying the total number of animals used and varying the sam-
pling time points. The zipper design allowed the sampling scheme
within each animal to be reduced in the new multiple-dose design
compared with the new single-dose design. This was thought to be
a more practical option for multiple-dose experiments where PD
information such as colony forming units or other biomarkers is
sampled within the same time frame as the PK. For the multiple-
dose oral zipper design, three or four samples per animal were eval-
uated but samples from at least one animal were also collected at
each of the other optimal sampling time points identiﬁed in the eval-
uation of the single-dose design, for each drug. In this way, data from
different animal groups receiving the same dosage but sampled at
different times were zipped together to contribute to the full PK pro-
ﬁle (Tables 1 to 4; Fig. 3). Data from the single-dose IV experiment
were included in the estimation of the new single- and multiple-
dose oral designs. Since the auto-induction of RIF in the PopPK
model was described using a separate clearance (CL) value only on
Day 3 rather than for the full time-course of RIF auto-induction, the
multiple-dose oral zipper design only included simulation of the PK
following a single dose but with the zipper PK sampling scheme. As
such, the RIF CL on Day 3 was not estimated in the SSE. Because the
half-lives of RIF, INH, EMB and PZA were short, the PK for the multi-
ple-dose experiments were obtained following a single dose, mim-
icking a PK occasion at any time during a PKPD experiment. The
last samples for the new designs for each drug and route of adminis-
tration were dependent on the LOQ for the observed data used for
building the PopPK models.
One thousand replicateswere simulated for each design, and each of
the simulated datasets was analysed using the ﬁnal PopPK model for
each drug, which was also used for the simulations. The designs were
assessed by estimating the rBias and relative imprecision. The latter
was expressed as the relative root mean square error (rRMSE). The
rBias and rRMSEwere derived as:
rBias ¼ 100%  1
N

X
i
estimationi−truei
truei
rRMSE ¼ 100% 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N

X
i
estimationi−trueið Þ2
true2i
vuut
where estimationi denotes the estimated parameter i value, truei is the
true parameter i value used in the initial simulations and N is the num-
ber of simulations for each set of truei (N= 1000).
3. Results
3.1. Rifampicin population pharmacokinetics
The observed blood concentrations of RIF after single-dose IV and
single- andmultiple-dose oral administrations using the original design
are shown in Fig. 1. A one-compartmentmodel with ﬁrst-order absorp-
tion and elimination provided the best ﬁt for the RIF PK data. The vol-
ume of distribution at the lowest dose of RIF (Vlowest dose) was
signiﬁcantly higher than that at higher doses (V). Neither a nonlinear
nor a linear relationship describing the change in Vwith dose was sup-
ported by the data. Due to auto-induction of RIF, clearance (CL) on Day 3
(132 mL/h/kg) was statistically signiﬁcantly higher than that on Days 1
and 2 (79.3 mL/h/kg). The bioavailability (F) was estimated as 65.6%.
The IIV of the absorption rate constant (ka), V/Vlowest dose and CLwere es-
timated as 55.6%, 21.8% and 15.9%, respectively. The data did not
Fig. 2. Prediction-corrected visual predictive checks (pcVPC) of A) rifampicin, B) isoniazid, C) ethambutol and D) pyrazinamide ﬁnal population pharmacokinetic models in the mouse
based on blood concentrations and the original experimental designs. The left panel shows the intravenous (IV) data, and the oral (PO) data are in the right panel. The black circles are
the prediction-corrected observed blood concentrations. The black solid lines are the medians of prediction-corrected observed data. The dark grey shaded areas are the simulation-
based 95% conﬁdence intervals for the medians. The observed 5% and 95% percentiles are presented as dashed grey lines and the 95% conﬁdence intervals for the corresponding
model-predicted percentiles are shown as light grey shaded areas.
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parameter estimates for RIF are presented in Table 5.
3.2. Isoniazid population pharmacokinetics
The observed blood concentrations of INH after single-dose IV and
single- andmultiple-dose oral administrations using the original design
are shown in Fig. 1. Isoniazid blood PK was best described using a one-
compartment PK model with dose-dependent V and CL. The CL de-
creased with increasing dose levels according to:
CL ¼ TVCL 1−CLMAX  dose−0:2ð Þ
CL50 þ dose−0:2ð Þ
 
where TVCL is the typical clearance at a dose of 0.2 mg/kg, CLMAX is the
maximumpercentage decrease in CL, and CL50 is the dose needed to ob-
tain 50% of CLMAX. The volume of distribution at a dose of 0.2 mg/kg
(Vlowest dose) was 1.8-fold lower than the V at higher doses. The IIV of
CL was estimated as 14.6%. The F of INH was estimated as 84.3%. The
ﬁnal PopPK parameter estimates for INH are presented in Table 5.3.3. Ethambutol population pharmacokinetics
The observed blood concentrations of EMB after single-dose IV and
single-dose oral administrations using the original design are shown
in Fig. 1. Ethambutol blood PK was described well by a two-compart-
ment model with an absorption lag time (Tlag) of 3.5 min and an F of
64%. The volumes of distribution of the central and peripheral compart-
ments (V and V2) were 2180 mL/kg and 4910 mL/kg, respectively. The
IIV was not estimated in the PK of EMB because of the very sparse orig-
inal design using only one sample per mouse. The ﬁnal PopPK parame-
ter estimates for EMB are presented in Table 5.3.4. Pyrazinamide population pharmacokinetics
The observed blood concentrations of PZA after single-dose IV and
single- andmultiple-dose oral administrations using the original design
are shown in Fig. 1. Pyrazinamide blood PK was best described using a
two-compartment PK model. The PZA CL was statistically lower at the
highest PZA dose (CLhighest dose) than at lower doses. The IIV of CL and
the inter-compartmental rate (Q) were estimated as 27.8% and
Fig. 3.Predicted blood concentrations versus time based on theﬁnal population pharmacokineticmodels after single-dose intravenous (IV) or single-dose oral (PO) or PO steady-state (SS)
administration of A) rifampicin, B) isoniazid, C) ethambutol and D) pyrazinamide. The sampling time points in the new designs for single-dose administration are indicated by * in each
plot. For themultiple-dose (zipper) oral administration designs, half of the animals were sampled according to ¤ in black and the other half according to ¤ in grey. For detailed information
about sampling time points, please see Tables 1–4.
325C. Chen et al. / European Journal of Pharmaceutical Sciences 93 (2016) 319–333118.7%, respectively, in the ﬁnal PZA PopPKmodel. The F of PZA was es-
timated as 55.9%. The ﬁnal PopPK parameter estimates for PZA are pre-
sented in Table 5.
3.5. Prediction-corrected visual predictive checks
The pcVPCs for RIF, INH, EMB and PZA PK, stratiﬁed by routes of ad-
ministrations, are shown in Fig. 2.
3.6. Optimisation of sampling designs
The last PK sample for each drug in the new designs was dependent
on the respective half-life and the LOQ of the drug, as the designs
targeted data above the LOQ. A sample was also taken at 24 h in the
new single-dose oral and IV designs for RIF and INH, since the rRMSE
values for some parameters were lower than those without a 24-hour
sample (data not shown). For the new single-dose oral design for PZA,
the last sampling timewas 4 h post-dose, sincemost of the observations
from the new simulated data were below the LOQ after the lower doses
at 4 h post-dose (data not shown). Pyrazinamide blood samples follow-
ing oral and IV administrationswere analysed using assayswith twodif-
ferent LOQ values. The LOQ for PZA blood concentrations was 100 ng/
mL after IV administration and 500 ng/mL after oral administration.
Therefore, the PK sampling times after PZA oral and IV administrations
were ended at 4 and 8 h post-dose, respectively. Due to the short half-
life of EMB, the 24-hour sample was deleted from the original design.
The sampling time points for the single-dose designs were assessedafter evaluation of the last sample taken for each drug. Several time
points were omitted from the original designs for each drug in order
to limit the designs to up to 8 samples from each mouse, covering the
whole experimental period up to the last sampling time point. For the
new single-dose IV and oral designs, the sampling time points of 0.25,
0.75 and 4 h post-dose were deleted from the original RIF design,
those of 1.5, 3 and 8 h post-dose were deleted from the original INH de-
sign, and those of 1.5, 3 and 24 h post-dose were deleted from the orig-
inal EMB design. In the new designs for PZA, the 3-hour post-dose
sampling time point was omitted from the original single-dose IV de-
sign and sample taking at 8 and 24 h post-dose was excluded from the
single-dose oral design. A new sampling time point was added at
0.08 h post-dose for the single-dose oral design and multiple-dose
oral zipper design, and another at 1.5 h post-dose was added to the
oral zipper design. For RIF, INH and EMB new single-dose designs, the
sampling time pointswere identical for the IV andoral studies. The sam-
pling time points for the investigated drugs and designs, and the pre-
dicted concentrations, are shown in Fig. 3.
The new optimised total number of animals required for the single-
dose designs were 24, 24, 33 and 33 for RIF, EMB, INH and PZA, respec-
tively. For RIF, INH and EMB, the numbers of animals required for the
new single-dose designswere up to 7-fold lower than in the original de-
signs (Tables 1–4). The number of animals required for PZA only de-
creased by 35% because the original sampling design already included
more than one sample per mouse.
The multiple-dose oral zipper designs were based on the sampling
time points that had been optimised for the new single-dose oral
326 C. Chen et al. / European Journal of Pharmaceutical Sciences 93 (2016) 319–333designs for RIF, INH, EMB and PZA. However, only four samples per
mouse were required for the zipper designs, compared to eight for the
single-dose designs. The re-estimation of data in the SSE for the zipper
design analysis used PK information from the single-dose IV and sin-
gle-dose oral experiments in order to include information about the bio-
availability and to use the richer sampling from the single-dose IV
experiment. The new optimised total numbers of animals required for
the multiple-dose oral zipper designs were 30, 30, 30 and 36 for RIF,
EMB, INH and PZA, respectively. For RIF, INH and EMB, these numbers
were almost 5-fold lower in the oral zipper designs than in the original
designs, which included up to 186 animals for each drug (Tables 1–4).
The required number of animals for PZA was similar to that in the orig-
inal design because more than one sample per mouse was also taken in
the original design. The rBias and rRMSE for each parameter, based on
the oral zipper designs (which included the new single-dose IV design
and eight samples per animal), were at least as low as those from the
new single-dose design for each drug. As shown in Figs. 4 and 5, the
rBias and rRMSE for each parameter in the new designs for each drug,
i.e. the oral zipper design with four samples per animal for multiple-
dose oral administration and the single-dose IV or oral design with up
to eight samples per animal, were similar or lower than those for the
original designs, except for the rBias in IIV for the CL of PZA, which
was 2% higher in the zipper design than in the original design. TheFig. 4. Relative bias [rBias (%)] of pharmacokinetic parameter estimates of A) rifampicin (RIF), B)
designs (dark grey bars), the new multiple-dose zipper designs (black bars), compared with th
and estimation and the new population pharmacokineticmodels. Inter-individual variability (II
one sample per animal. The ﬁnal population pharmacokinetic model for EMB did not include IrBias in the INH CL50 was also 6% and 3% higher in the new single-dose
and zipper designs than in the original design.
4. Discussion
This study describes the PopPK of RIF, INH, PZA and EMB in the
mouse, using blood concentrations and nonlinear mixed effects model-
ling (Table 5). In addition, the sampling designs were optimised to re-
duce the number of animals required. Careful design is important for
animal experiments from an ethical perspective as well as in order to
save money and increase the information content of a study.
Before a PK-PD experiment is done for a new compound, the PK after
a single dose needs to be deﬁned. We therefore explored an optimised
single-dose design for the four chosen anti-TB drugs. The most impor-
tant design aspect was to increase the number of samples taken from
each animal to up to eight samples per mouse, a number which was
judged to be practical and ethical. Using the ﬁnal PopPKmodels,we per-
formed simulations using an SSE approach in order to derive optimal PK
sampling designs and total population sizes for each of the four anti-TB
drugs. In an SSE approach, data is simulated based on a model and then
re-estimated based on different designs of interest in order to investi-
gate the bias and imprecision in parameter estimates. We found that
changing the design from one sample per animal to up to eight samplesisoniazid (INH), C) ethambutol (EMB) andD) pyrazinamide (PZA) for the new single-dose
e original designs (light grey bars). The results were obtained using stochastic simulation
V)was not re-estimated in the original designs for RIF and INH as the designs only included
IV.
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without compromising the precision of the PK parameters in the sin-
gle-dose designs.
Traditionally, PK is determined in satellite experiments and the data
are then used as ﬁxed PK input in PK-PD models for TB (Chen et al.,
2014). The design would, of course, be more informative if the PK and
PD are obtained in the same animal.With such a design inmind, we de-
veloped the oral zipper design which obtains the PK of the drug after
one dose in a multiple-dose experiment. In this design, only four sam-
ples are taken per animal but all the samples from all the animals are
zipped together to cover the entire sampling period. Similarly, for the
multiple-dose oral zipper design, changing the sampling design from
one sample per animal to four samples per animal decreased the num-
ber of animals required by up to 5-fold. The four drugs that we have
studied are part of the standard clinical treatment of drug-susceptible
TB and are often used as a control in PD experiments. As such, the sug-
gested optimised PK designs can be used in future PK-PD experiments
with these drugs as controls. For new compounds, the lessons learnt
from this work are the advantages of using serial sampling instead of
single sample designs. However, if the PK is not known for a new com-
pound, there is no standard sampling series that can ﬁt for drugs with
both short and long half-lives. We therefore suggest that a small pilot
experiment is done with a zipper design where the samples are taken
in order to collect some information. Based on the information fromthe initial work, the design can be optimised as done in this study.
This is also in agreement with the learning-conﬁrming paradigm
(Sheiner, 1997).
It is important to notice that the PK in this study was based on the
blood concentrations of the four anti-TB drugs. The data in PK are de-
pendent on whether blood, plasma, saliva, etc. is sampled, and PK data
based on plasma samples would potentially be different from those
based on blood samples. In the original data/design, single-dose admin-
istrations of RIF and INH did not include information on IIV, since only
one sample from eachmousewas taken. However, it was possible to es-
timate IIV due to the simultaneous ﬁt of single- and multiple-dose data
andmultiple sampleswere taken frommice aftermultiple-dose oral ad-
ministrations of RIF and INH.However, no repeatedwithin-animal sam-
pling was obtained for EMB. Therefore the ﬁnal PopPK model for EMB
did not include IIV. All original data/designs for PZA included repeated
within-animal sampling and theﬁnal PopPKmodel for PZA therefore in-
cluded estimation of IIV.
The PopPK of RIF, INH, PZA and EMBwas established in healthymice
in thiswork. It is not known if the PKwould be different inmice infected
withM. tuberculosis but it cannot be ruled out. For instance, the terminal
half-life of RIF was reported to be 4.4 h (de Steenwinkel et al., 2013) and
12 h (Jayaram et al., 2003) in the BALB/c mouse, and 7.6 h in the Swiss
mouse (Ji et al., 1993). This should be compared to a half-life of approx-
imately 6.6 h in our study using the C57BL/6 mouse. The PK of RIF
Fig. 4 (continued).
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ministration of 10 mg/kg RIF to the BALB/c mouse for ﬁve days, there
was a reduction in plasma exposure on Day 5 compare to Day 1
(Hosagrahara et al., 2013). We also found in this work that CL of RIF in
blood on Day 3 (132 mL/h/kg) was signiﬁcantly higher than that on
Days 1 and 2 (79.3 mL/h/kg). Isoniazid was found to display dose-de-
pendent V and CL in a dose range of 0.2–25 mg/kg in our study. An ear-
lier study showed linear PK for INH in the dose range of 0.1–120mg/kg
using the BALB/c mouse (Jayaram et al., 2004). The terminal half-life of
25 mg/kg of INH in serum using the Swiss mouse has been reported to
be 1.7 ± 0.17 h (Grosset et al., 1992), and approximately 1.4 h in
blood using the C57BL/6 mouse in our study. The maximum concentra-
tion of 25mg/kg of INH in serumwas 22 μg/mL using the BALB/c mouse
(Almeida et al., 2009), and approximately 21 μg/mL in blood in our
study. The peak concentration of radioactive EMB 14C labelled occurred
at 2 h after 32 mg/kg (Kelly et al., 1981) using Charles River mouse. The
peak concentration of 30 mg/kg EMB in this work occurred at approxi-
mately 0.75 h after dose. Pyrazinamide was found to display dose-de-
pendent CL in a dose range of 15–1000 mg/kg in our study using the
C57BL/6 mouse where CL at 15–400 mg/kg was estimated to approxi-
mately 515 mL/h/kg and 95mL/h/kg at 1000mg/kg, whereas it was es-
timated to 460mL/h/kg in the BALB/c mouse and to 410mL/h/kg in the
C3HeB/FeJ mouse (Irwin et al., 2016) at 150 mg/kg. Since efﬁcacy stud-
ies in the mouse model involve chronic dosing, it is essential tounderstand the PK behaviour of anti-TB compounds following repeated
oral administration. The observed systemic exposure after a single dose
may be different from that after multiple-dose administrations if the
compound has the potential to induce or inhibit clearance or absorption
mechanisms, leading to dose- or time-dependent PK. In humans, RIF is a
known inducer of cytochrome P450 (Combalbert et al., 1989) and P-gly-
coprotein through activation of the nuclear pregnane X receptor (Geick
et al., 2001), which causes potential for drug-drug interactions. Full
steady-state RIF auto-induction in humans is reached after 40 days of
oral dosage (Smythe et al., 2012). In this study, RIF CL on Day 3was pre-
dicted to be 66.4% higher than on Days 1 and 2, which indicates that RIF
is auto-induced not only in humans, but also in the mouse. However, a
more mechanistic model estimating the enzyme turn-over could not
be quantiﬁed because of the short PK sampling period. More research
is required in order to evaluate the turnover of RIF auto-induction in
the mouse. It is very important to notice that humans may differ from
animalswith regard to expression and catalytic activities of drugmetab-
olizing enzymes. For instance, cytochromeP450 2B (CYP2B)was not de-
tectable in the human intestine (Kaminsky and Zhang, 2003), but
expressed in the intestine of mouse (Martignoni et al., 2005). Although
animal models are not expected to always predict drug exposure in
human, they serve as valuable tools for quantifying exposure-response
relationships and ideally predict response at certain dose levels in
human.
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quite quickly below the LOQ. Although samples below the LOQ
can be included in a PopPK analysis using the M3method, it is pref-
erable to sample concentrations above the LOQ. In our studies, dif-
ferent LOQ values, arising from different mass spectrometry
analyses used in the animal studies, were used for IV (100 ng/mL)
and oral (500 ng/mL) PZA concentrations. Since the different LOQ
values used for oral and IV administrations of PZA could have had
an impact on the study design, we made the last sampling time
points for IV and oral administration at 8 and 4 h post-dose,
respectively.
The Vlowest dose for RIF was higher than the V for the other doses. The
Vlowest dose for INH was also different but, in contrast to RIF, it was lower
than V for the other doses. Dose-dependent CL was identiﬁed for INH
and PZA. The mechanisms behind the dose-dependent PK identiﬁed in
this work remain unknown. Mechanistic information is important but,
from a PK-PD modelling perspective, empirical models as used in the
ﬁnal PopPK models presented here will be predictive within the dose
ranges studied and will be able to provide useful exposure input for
PK-PD modelling exercises.
5. Conclusions
The new single-dose design with enrichened individual sam-
pling was more informative than the original design in which only
one sample was taken from each mouse. The proposed oral zipper
design allows informative PK sampling in a multiple-dose adminis-
tration scenario for characterising PK-PD relationships. Simulations
showed that the suggested improved designs resulted in similar orlower biases and imprecisions in parameter estimates, and de-
creased the total number of animals required by up to 7-fold com-
pared to the original designs where only one sample was taken
from each animal.
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